BBI Brickell Biotech Inc

Brickell Biotech to Report Second Quarter 2020 Financial Results and Provide a Corporate Update on August 12, 2020

Brickell Biotech to Report Second Quarter 2020 Financial Results and Provide a Corporate Update on August 12, 2020

BOULDER, Colo., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases, today announced that it will report its financial results for the second quarter ended June 30, 2020, after the market close on Wednesday, August 12, 2020. Brickell’s management will host a conference call and webcast at 4:30pm ET to discuss the financial results and recent corporate highlights.

To access the call, please dial 877-705-6003 in the U.S. or 201-493-6725 outside the U.S. and provide the conference ID number: 13706625. To access the live webcast, please go to the investors section of Brickell’s website at . Following the live webcast, an archived version of the call will be available on the website.

About Brickell Bio

Brickell Biotech, Inc. is a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases. Brickell’s pipeline consists of potential novel therapeutics for hyperhidrosis and other prevalent dermatological conditions. Brickell’s executive management team and board of directors bring extensive experience in product development and global commercialization, having served in leadership roles at large global pharmaceutical companies and biotechs that have developed and/or launched successful products, including several that were first-in-class and/or achieved iconic status, such as Cialis®, Taltz®, Gemzar®, Prozac®, Cymbalta® and Juvederm®. Brickell’s strategy is to leverage this experience to in-license, acquire, develop, and commercialize innovative products that Brickell believes can be successful in the currently underserved dermatology global marketplace. For more information, visit .

Brickell Investor Contact:

 

EN
03/08/2020

Underlying

BBIBrickell Biotech Inc

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Brickell Biotech Inc

 PRESS RELEASE
Free
BBI Brickell Biotec...

Brickell Biotech Reports Second Quarter 2022 Financial Results and Pro...

Brickell Biotech Reports Second Quarter 2022 Financial Results and Provides Corporate Update Phase 1 study of BBI-02 progressing well and expect to initiate MAD part of the study next month On track to report SAD and MAD topline results from BBI-02 Phase 1 study by early 2023 Development of BBI-10 and next-generation kinase inhibitors advancing through early preclinical stage studies BOULDER, Colo., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell” or the “Company”) (Nasdaq: BBI), a clinical-stage pharmaceutical company striving to transform patient lives by de...

August 11, 2022 1 EN
 PRESS RELEASE
Free
BBI Brickell Biotec...

Brickell Biotech to Report Second Quarter 2022 Financial Results and P...

Brickell Biotech to Report Second Quarter 2022 Financial Results and Provide a Corporate Update on August 11, 2022 BOULDER, Colo., Aug. 02, 2022 (GLOBE NEWSWIRE) -- (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases, today announced that it will report its second quarter financial results on Thursday, August 11th. Brickell’s management will host a conference call and webcast at 4:30 p.m. E...

August 2, 2022 1 EN
 PRESS RELEASE
Free
BBI Brickell Biotec...

Brickell Biotech Regains Compliance with Nasdaq Minimum Bid Price Requ...

Brickell Biotech Regains Compliance with Nasdaq Minimum Bid Price Requirement BOULDER, Colo., July 20, 2022 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases, today announced that it received formal notice from The Nasdaq Stock Market (“Nasdaq”) stating that Brickell has regained compliance with the minimum bid price requirement for continued list...

July 20, 2022 1 EN
 PRESS RELEASE
Free
BBI Brickell Biotec...

Brickell Biotech Announces 1-For-45 Reverse Stock Split

Brickell Biotech Announces 1-For-45 Reverse Stock Split Common stock will begin trading on a split-adjusted basis on July 5, 2022 BOULDER, Colo., July 01, 2022 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell” or the “Company”) (Nasdaq: BBI), a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases, today announced that at the special meeting of stockholders held on June 30, 2022, the Company’s stockholders approved ...

July 1, 2022 1 EN
 PRESS RELEASE
Free
BBI Brickell Biotec...

Brickell Biotech Doses First Subject in Phase 1 Study of DYRK1A Inhibi...

Brickell Biotech Doses First Subject in Phase 1 Study of DYRK1A Inhibitor BBI-02 – BBI-02 is a potential first-in-class, oral DYRK1A inhibitor with strong preclinical validation and broad potential to treat debilitating autoimmune and inflammatory diseases – – Topline results from the SAD and MAD parts of the Phase 1 study expected to be announced by early 2023 – BOULDER, Colo., May 19, 2022 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell” or the “Company”) (Nasdaq: BBI), a clinical-stage pharmaceutical company striving to transform patient lives by developing innovati...

May 19, 2022 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch